Brigatinib: up next in our pipeline

An FDA breakthrough therapy under investigation in ALK+ NSCLC

LEARN MORE

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

7/5/16
ARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results
Read More
6/24/16
ARIAD Announces Webcast of Its Annual Stockholders Meeting
Read More
 

TWITTER FEED